Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
European Journal of Nuclear Medicine and Molecular Imaging
Published in: European Journal of Nuclear Medicine and Molecular Imaging 5/2007

01-05-2007 | Image of the month

Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation

Authors: C. von Falck, A. R. Boerner, M. Galanski, W. H. Knapp

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 5/2007

Login to get access

Excerpt

The diagnostic value of 18F-FDG PET is known to be limited in neuroendocrine malignancies because only poorly differentiated tumours demonstrate a markedly increased glucose metabolism [1]. 68Ga-DOTATOC is a somatostatin analogue for highly sensitive and specific PET imaging of neuroendocrine tumours, with a high affinity for the human SSTR2 [2]. It shows promising results for the evaluation of patients with metastatic disease and the selection of patients scheduled for radionuclide therapy [3]. …
Literature
1.
Adams S, Baum R, Rink T, Schumm-Dräger PM, Usadel KH, Hör G. Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumors. Eur J Nucl Med 1998;25:79–83.CrossRefPubMed
2.
Maecke H, Hofmann M, Haberkorn U. 68-Ga-labeled peptides in tumor imaging. J Nucl Med 2005;46 Suppl 1:172–8.
3.
Koukouraki S, Strauss LG, Georgoulias V, Eisenhut M, Haberkorn U, Dimitrakopoulou-Strauss A. Comparison of the pharmakokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 2006;33:1115–22.CrossRefPubMed
Metadata
Title
Neuroendocrine tumour of the mediastinum: fusion of 18F-FDG and 68Ga-DOTATOC PET/CT datasets demonstrates different degrees of differentiation
Authors
C. von Falck
A. R. Boerner
M. Galanski
W. H. Knapp
Publication date
01-05-2007
Publisher
Springer Berlin Heidelberg
Published in
European Journal of Nuclear Medicine and Molecular Imaging / Issue 5/2007
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-006-0350-9

Other articles of this Issue 5/2007

European Journal of Nuclear Medicine and Molecular Imaging 5/2007 Go to the issue

Book Review

Michael E. Phelps (ed) PET: physics, instrumentation and scanners. Springer, New York, 2006, 130 pp, 77 illustrations. Hardcover. $59.95. ISBN-10: 0-387-32302-3, ISBN-13: 978-0-387-32302-2

Original Article

Quantification of adenosine A2A receptors in the human brain using [11C]TMSX and positron emission tomography

Focus on...

The emergence of MRI and MSCT cardiac imaging: nuclear cardiology is not the only actor on the stage

Book review

International Atomic Energy Agency: Nuclear medicine resources manual. 2006. IAEA, Vienna, 532 pp., 55 illustrations. €65.00. ISBN 92-0-107504-9.

Erratum

Erratum to Abstracts of the Annual Congress of the EANM, Athens, Greece, 2006

Editorial

Is a methodology available that accurately measures the cost of an FDG-PET study?